Status:

UNKNOWN

A Randomized Controlled Clinical Trial of Surgery Versus Conservative Treatment for Mild and Moderate-grade Nasopharyngeal Necrosis

Lead Sponsor:

Sun Yat-sen University

Conditions:

Nasopharyngeal Carcinoma, Postradiation, Necrosis, Endoscopy Surgery, Conservative Treatment

Eligibility:

All Genders

18-70 years

Phase:

NA

Brief Summary

Post radiation nasopharyngeal necrosis is a relatively special radiotherapy sequelae after radiotherapy for nasopharyngeal carcinoma. According to the degree of its development, it can be roughly divi...

Eligibility Criteria

Inclusion

  • Received radical radiotherapy for the nasopharynx;
  • For patients with early-stage and mid-stage nasopharyngeal necrosis diagnosed for the first time by clinical symptoms, imaging examinations and pathology. The lesions are limited to the superficial tissue of the nasopharynx and the deep tissue of each wall of the nasopharynx, regardless of the exposure of internal carotid artery invasion(ICA). For those patients with ICA exposure, vascular pretreatment (vascular embolization or bypass surgery) would be performed and reassess after 2-4 weeks of vascular treatment.
  • The patient has signed the informed notice and is willing and able to comply with the study plan visits, treatment plans, laboratory tests and other study procedures.

Exclusion

  • Karnofsky score ≤ 70 points or Zubrod score \> 2 points;
  • Patients with severe medical complications, insufficiency of important organs (heart, lung, liver, kidney) or neuropsychiatric disorders at the time of diagnosis.
  • Patients with pathologically confirmed local recurrence.
  • Cases who have received local nasal cavity and nasopharyngeal surgery in the past.
  • Patients who cannot cooperate with regular follow-up due to psychological, social, family and geographical reasons.
  • Other patients who are considered unsuitable for inclusion by the treating physician.

Key Trial Info

Start Date :

November 1 2021

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

October 30 2024

Estimated Enrollment :

216 Patients enrolled

Trial Details

Trial ID

NCT05228093

Start Date

November 1 2021

End Date

October 30 2024

Last Update

February 8 2022

Active Locations (4)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (4 locations)

1

Department of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center

Guangzhou, Guangdong, China, 510060

2

The First Affiliated Hospital, Sun Yat-Sen University

Guangzhou, Guangdong, China, 510080

3

The Fifth Affiliated Hospital of Guangzhou Medical University

Guangzhou, Guangdong, China, 510700

4

The First Hospital of Nanchang

Nanchang, Jiangxi, China, 330000